Skip to content

TINO: T Cells in the Nose of Older Adults

TINO: Identifying the Underlying Mechanisms and Consequences of the Loss of Nasal T Cells in Vital and Frail Older Individuals

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06039527
Acronym
TINO
Enrollment
125
Registered
2023-09-15
Start date
2021-01-24
Completion date
2025-10-10
Last updated
2026-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging, Respiratory Tract Infections

Brief summary

Rationale: Individuals with advanced age are at a progressively increasing risk of acquiring lower respiratory tract infections. Besides calendar age, the degree of frailty also associates with increased susceptibility to pneumonia requiring hospitalization. How alterations in the mucosal immune system with advanced age predispose to infections remains unclear as access to relevant tissue samples is limited. With minimally-invasive nasal sampling methods, it was recently observed that in vital older adults, both CD4+ T cells and CD8+ T cells are selectively lost from the nasal mucosa. However, the exact phenotype, underlying mechanisms, key molecules and consequences of this have not yet been investigated. Objective: Elucidate the mechanisms underlying the loss of nasal T cells and characterize in depth the differences of T cells in young and older adults and associate this loss with susceptibility to infections. Study design: Prospective cohort study Study population: Participants will be recruited from 3 groups: * healthy young adults (18-30 years, n=50) * vital older adults (\>65 years, n=60) * frail elderly (\>65 years, n=60). This group includes individuals without a history of recurrent respiratory infections or with \>2 self-reported episodes of respiratory infection in the past year. Main study parameters/endpoints: Frequency of nasal CD8+ T cells in young adults and frail older adults. Secondary study parameters/endpoints: * Phenotype (subsets, activation status), functionality, transcriptomic state, clonality and frequency of nasal and blood T cell populations * Stability of T cells and other immune parameters, as described for main study parameter, during a second sample after 3 months. * Analysis of other immune populations as for main study parameter * Concentration of nasal and systemic factors (e.g. cytokines and metabolites) and their association with T cells and other immune populations * Respiratory tract microbiota profiles and presence of asymptomatic viral infections and their association with T cells and other immune parameters * Chronological and biological age, sex, and other immunologically relevant parameters with T cell populations and other immune parameters * Alteration of T cell phenotype, during and following respiratory tract infections. Levels of antigen-specific T cells and other immune parameters in nose and blood post infection.

Interventions

None listed

Sponsors

Leiden University Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

•Adults able and willing to provide informed consent. Specific inclusion criteria per group: * Young adults aged 18-30 years old * Healthy elderly aged \>65 years old * Frail elderly \>65 years old * Clinical Frailty score healthy elderly 1-3 * Clinical Frailty score frail elderly \>3 * Self-reported respiratory tract infection in previous year healthy elderly 0-1 * Self-reported respiratory tract infection in previous year frail elderly 0-1 or \>1

Exclusion criteria

* Incompetence to provide informed consent prior or during study * Current smoker or \>40 pack year history * History of severe nose bleedings * Diagnosed with asthma, COPD or chronic rhinosinusitis * Use of inhalation corticosteroids or antibiotics in the past 6 weeks * Current use of anti-coagulants (to prevent nosebleeds). Platelet inhibitors like acetylsalicylzuur (Ascal) are allowed. * Respiratory tract infection or common cold in the past 2 weeks * Immunocompromised individuals (with primary immune deficiency or secondary immune deficiency) * Life expectancy \<28 days in the opinion of study physician * Vaccination in the 2 months prior to study start. A potential subject that is only excluded from participation based on a recent vaccination will be asked to re-participate 2 months post vaccination.

Design outcomes

Primary

MeasureTime frameDescription
Frequency of nasal CD8+ T cells in young adults and frail older adults.baseline sample or month 3 sampleCD8 T cells relative to nasal epithelial cells (ratio)

Secondary

MeasureTime frameDescription
Phenotype of nasal and blood T cell populations in young adults, healthy older adults and frail older adults that suffer from recurrent respiratory tract infections or not.baseline sample or month 3 samplepercentage of T cells and T cell subsets
Functionality of nasal and blood T cell populations in young adults, healthy older adults and frail older adults that suffer from recurrent respiratory tract infections or not.baseline sample or month 3 samplepercentage of T cells responding to in vitro stimulations
Transcriptomic cluster composition of nasal and blood T cell populations in young adults, healthy older adults and frail older adults that suffer from recurrent respiratory tract infections or not, as frequency of T cell subsets.baseline sample or month 3 sampleT cell clusters based on gene expression patterns
Clonality of nasal and blood T cell populations in young adults, healthy older adults and frail older adults that suffer from recurrent respiratory tract infections or not.baseline sample or month 3 sampleNumber and proportion of TCR clones
Stability of nasal T cells, as described for main study parameter, during a second sample after 3 months.baseline sample versus month 3 sampleCD8 T cells relative to nasal epithelial cells (ratio)
Stability of nasal immune populations, during a second sample after 3 months.baseline sample versus month 3 sampleimmune cell populations relative to nasal epithelial cells (ratio)
Comparison of nasal immune cell populations between young adults, vital and frail elderlybaseline sample or month 3 sampleratio to epithelial cells
Comparison of peripheral immune cell populations between young adults, vital and frail elderlybaseline sample or month 3 samplepercentage of total CD45+ cells
Concentration of nasal and systemic cytokinesbaseline sample or month 3 sampleconcentrations
Concentration of nasal and systemic metabolitesother immune populationsbaseline sample or month 3 sampleconcentrations
Respiratory tract microbiota profiles and their association with T cells and other immune parametersbaseline sample or month 3 samplemicrobiota abundance (total sum scaling)
Presence of asymptomatic viral infections and their association with T cells and other immune parametersbaseline sample or month 3 sampleviral of loads (Ct)
Effect of sex on aging effects of nasal immune populationsbaseline sample or month 3 sampleratio to nasal epithelial cells
Effect of sex on aging effects of blood immune populationsbaseline sample or month 3 samplepercentage of CD45+ cells
Frequencies of antigen-specific T cells in nose post infection.symptom onset and 1, 3 and 5 months laterantigen-specific T cells as percentage of T cells
Frequencies of antigen-specific T cells in blood post infection.symptom onset and 1, 3 and 5 months laterantigen-specific T cells as percentage of T cells

Countries

Netherlands

Contacts

PRINCIPAL_INVESTIGATORSimon P Jochems, PhD

LUMC

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 8, 2026